Literature DB >> 12036453

Inhibition of nucleotide excision repair by fludarabine in normal lymphocytes in vitro, measured by the alkaline single cell gel electrophoresis (Comet) assay.

Takahiro Yamauchi1, Yasukazu Kawai, Takanori Ueda.   

Abstract

Alkylating agents or platinum analogues initiate several excision repair mechanisms, which involve incision of the DNA strand, excision of the damaged nucleotide, gap filling by DNA resynthesis, and rejoining by ligation. The previous study described that nucleotide excision repair permitted incorporation of fludarabine nucleoside (F-ara-A) into the repair patch, thereby inhibiting the DNA resynthesis. In the present study, to clarify the repair kinetics in view of the inhibition by F-ara-A, normal lymphocytes were stimulated to undergo nucleotide excision repair by ultraviolet C (UV) irradiation in the presence or absence of F-ara-A. The repair kinetics were determined as DNA single strand breaks resulting from the incision and the rejoining using the alkaline single cell gel electrophoresis (comet) assay. DNA resynthesis was evaluated in terms of the uptake of tritiated thymidine into DNA. The lymphocytes initiated the incision step maximally at 1 h, and completed the rejoining process within 4 h after UV exposure. UV also initiated thymidine uptake, which increased time-dependently and reached a plateau at 4 h. A 2-h pre-incubation with F-ara-A inhibited the repair in a concentration-dependent manner, with the maximal inhibition by 5 mM. This inhibitory effect was demonstrated by the reduction of the thymidine uptake and by the inhibition of the rejoining. A DNA polymerase inhibitor, aphidicolin, and a ribonucleotide reductase inhibitor, hydroxyurea, were not so inhibitory to the repair process as F-ara-A at equimolar concentrations. The present findings suggest that inhibition of nucleotide excision repair may represent a novel therapeutic strategy against cancer, especially in the context of resistant cells with an increased repair capacity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036453      PMCID: PMC5927026          DOI: 10.1111/j.1349-7006.2002.tb01292.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  30 in total

Review 1.  Quality control by DNA repair.

Authors:  T Lindahl; R D Wood
Journal:  Science       Date:  1999-12-03       Impact factor: 47.728

2.  Leukocyte preparations from human blood: evaluation of their morphologic and metabolic state.

Authors:  H J FALLON; E FREI; J D DAVIDSON; J S TRIER; D BURK
Journal:  J Lab Clin Med       Date:  1962-05

3.  Enhancement of excision repair of cisplatin-DNA adducts by cell-free extract from a cisplatin-resistant rat cell line.

Authors:  Y Hibino; Y Hiraoka; S Kamiuchi; E Kusashio; N Sugano
Journal:  Biochem Pharmacol       Date:  1999-06-15       Impact factor: 5.858

Review 4.  The comet assay: a comprehensive review.

Authors:  D W Fairbairn; P L Olive; K L O'Neill
Journal:  Mutat Res       Date:  1995-02       Impact factor: 2.433

5.  The roles of DNA polymerases alpha, beta, and gamma in DNA repair synthesis induced in hamster and human cells by different DNA damaging agents.

Authors:  M R Miller; D N Chinault
Journal:  J Biol Chem       Date:  1982-09-10       Impact factor: 5.157

6.  The DNA repair inhibitors hydroxyurea and cytosine arabinoside enhance the sensitivity of the alkaline single-cell gel electrophoresis ('comet') assay in metabolically-competent MCL-5 cells.

Authors:  F L Martin; K J Cole; M H Orme; P L Grover; D H Phillips; S Venitt
Journal:  Mutat Res       Date:  1999-09-15       Impact factor: 2.433

Review 7.  Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA.

Authors:  A L Pinto; S J Lippard
Journal:  Biochim Biophys Acta       Date:  1985

8.  In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.

Authors:  W C Tseng; D Derse; Y C Cheng; R W Brockman; L L Bennett
Journal:  Mol Pharmacol       Date:  1982-03       Impact factor: 4.436

Review 9.  Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.

Authors:  W Plunkett; V Gandhi; P Huang; L E Robertson; L Y Yang; V Gregoire; E Estey; M J Keating
Journal:  Semin Oncol       Date:  1993-10       Impact factor: 4.929

10.  Hydroxyurea: effects on deoxyribonucleotide pool sizes correlated with effects on DNA repair in mammalian cells.

Authors:  A Collins; D J Oates
Journal:  Eur J Biochem       Date:  1987-12-01
View more
  5 in total

1.  Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine-mediated inhibition of enhanced nucleotide excision repair in leukemia.

Authors:  Kazutaka Takagi; Yasukazu Kawai; Takahiro Yamauchi; Hiromichi Iwasaki; Takanori Ueda
Journal:  Int J Hematol       Date:  2011-09-23       Impact factor: 2.490

2.  Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.

Authors:  Mazin A Moufarij; Deepa Sampath; Michael J Keating; William Plunkett
Journal:  Blood       Date:  2006-09-05       Impact factor: 22.113

3.  Expanded usage of the Challenge-Comet assay as a DNA repair biomarker in human populations: protocols for fresh and cryopreserved blood samples, and for different challenge agents.

Authors:  Vanessa Valdiglesias; María Sánchez-Flores; Natalia Fernández-Bertólez; William Au; Eduardo Pásaro; Blanca Laffon
Journal:  Arch Toxicol       Date:  2020-09-30       Impact factor: 5.153

4.  1-beta-D-arabinofuranosylcytosine is cytotoxic in quiescent normal lymphocytes undergoing DNA excision repair.

Authors:  Takahiro Yamauchi; Yasukazu Kawai; Takanori Ueda
Journal:  Jpn J Cancer Res       Date:  2002-12

Review 5.  Signaling Pathways, Chemical and Biological Modulators of Nucleotide Excision Repair: The Faithful Shield against UV Genotoxicity.

Authors:  F Kobaisi; N Fayyad; H R Rezvani; M Fayyad-Kazan; E Sulpice; B Badran; H Fayyad-Kazan; X Gidrol; W Rachidi
Journal:  Oxid Med Cell Longev       Date:  2019-08-07       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.